- Home
- FOFO vs SCNX Comparison
FOFO vs SCNX Comparison
Compare FOFO & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FOFO | SCNX |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Other Pharmaceuticals |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 16.2M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FOFO | SCNX |
|---|---|---|
| Price | $1.76 | $2.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.1K | ★ 24.1K |
| Earning Date | 12-04-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,831,778.00 |
| Revenue This Year | N/A | $743.36 |
| Revenue Next Year | N/A | $325.03 |
| P/E Ratio | $11.09 | ★ N/A |
| Revenue Growth | N/A | ★ 30.72 |
| 52 Week Low | $1.58 | $2.64 |
| 52 Week High | $14.93 | $106.25 |
Technical Indicators
Market Signals| Indicator | FOFO | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 46.48 |
| Support Level | $1.76 | $2.64 |
| Resistance Level | $1.97 | $3.68 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | 0.00 | 0.24 |
| Stochastic Oscillator | 41.86 | 9.29 |
Price Performance
Historical ComparisonAbout FOFO Hang Feng Technology Innovation Co. Ltd. Ordinary Shares
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their business and investment objectives. Its business consists of two main business lines: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting and Regulatory compliance and governance consulting, and the asset management services, including fund subscription and fund management services.
About SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.